NEW YORK (GenomeWeb News) – Strategic Diagnostics and the Fred Hutchinson Cancer Center said yesterday that they will collaborate to discover biomarkers for use in the early detection of a variety of cancers.

Under the collaboration, which will initially focus on pancreatic cancer, Newark, NJ-based SDI will provide approximately 1,000 of its cancer antigen antibodies to Paul Lampe, full member and associate program head of the Molecular Diagnostics Program at Seattle's Hutchinson Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.